Specific Molecular Targets to Control Tropical Diseases

Author: Rodriguez, J.B.

Source: Current Drug Metabolism, Volume 7, Number 12, 1 August 2001 , pp. 1105-1116(12)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Chagas disease or American trypanosomiasis is considered by the Word Health Organization to be one of the important tropical parasitic diseases worldwide together with malaria and schistosomiasis. The etiologic agent of this illness is the kinetoplastid protozoon Trypanosoma cruzi. The present chemotherapy for the treatment of Chagas disease remains unsolved. The drugs currently in use are old, ineffective and toxic. Bearing in mind the metabolic differences between the parasite and the mammalian host, some attractive interesting molecular targets for drug design are presented.

Keywords: Molecular Targets; Tropical Diseases; Chagas disease; Malaria; schistosomiasis; Trypanosoma cruzi; Inhibitors; 4-PhenoxyphenoxyethylAllyl Ether; Tetrahydro-2H-pyran- 2-yl Ether; Potent Sulfur-containing Derivatives

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397555

Publication date: 2001-08-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.